Winthrop Advisory Group LLC Buys 397 Shares of Pfizer Inc. (NYSE:PFE)

Winthrop Advisory Group LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 2.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 15,834 shares of the biopharmaceutical company’s stock after acquiring an additional 397 shares during the quarter. Winthrop Advisory Group LLC’s holdings in Pfizer were worth $458,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Verity Asset Management Inc. grew its position in Pfizer by 31.5% during the third quarter. Verity Asset Management Inc. now owns 64,136 shares of the biopharmaceutical company’s stock worth $1,851,000 after buying an additional 15,364 shares in the last quarter. Lewis Asset Management LLC grew its position in Pfizer by 16.7% during the third quarter. Lewis Asset Management LLC now owns 32,839 shares of the biopharmaceutical company’s stock worth $950,000 after buying an additional 4,695 shares in the last quarter. Mine & Arao Wealth Creation & Management LLC. acquired a new stake in Pfizer during the third quarter worth about $203,000. Beacon Harbor Wealth Advisors Inc. grew its position in Pfizer by 1.4% during the third quarter. Beacon Harbor Wealth Advisors Inc. now owns 236,210 shares of the biopharmaceutical company’s stock worth $6,836,000 after buying an additional 3,169 shares in the last quarter. Finally, Mainstream Capital Management LLC acquired a new stake in Pfizer during the third quarter worth about $1,042,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PFE shares. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Citigroup initiated coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Price Performance

PFE stock opened at $27.46 on Friday. The stock has a 50-day moving average price of $28.96 and a two-hundred day moving average price of $28.64. The stock has a market cap of $155.62 billion, a PE ratio of 37.11, a price-to-earnings-growth ratio of 0.88 and a beta of 0.67. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The company’s revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.17) EPS. Equities analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.12%. Pfizer’s dividend payout ratio is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.